[Management of metastatic HER2-positive breast cancer: present and future]
- PMID: 20176546
- DOI: 10.1684/bdc.2010.1040
[Management of metastatic HER2-positive breast cancer: present and future]
Abstract
HER2-positive breast cancer accounts for 20 to 25% of breast cancers. The surexpression of this tyrosine-kinase receptor is often associated with a poor prognosis. However, the management and the outcome of these patients have changed these last ten years with trastuzumab. Despite the encouraging results obtained with this humanized monoclonal antibody directed against the HER2-receptor, used alone or in association with chemotherapy in metastatic patients, progression under trastuzumab are usually observed and resistances to this treatment are described. Thus, many other monoclonal antibodies and tyrosine-kinase inhibitors emerged. These therapeutics, used alone or in association with chemotherapy or trastuzumab have variable properties: anti-HER2 and anti-EGFR such as lapatinib, pertuzumab and neratinib; anti-EGFR such as erlotinib and gefitinib; antiangiogenesis (bevacizumab, pazopanib); anti-mTOR pathway (temsirolimus, everolimus) or inhibitor of HSP90 (tanespimycine). In this paper, we present an overview on validated targeted therapies and those which are currently under investigation and seem promising in first line or after progression under trastuzumab. Data regarding cardiotoxicity and the use of trastuzumab under particular clinical circumstances (brain metastases, pregnancy) are also reviewed.
Similar articles
-
Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.Mol Pharm. 2012 Nov 5;9(11):2995-3002. doi: 10.1021/mp3002182. Epub 2012 Oct 11. Mol Pharm. 2012. PMID: 23003202
-
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.Cancer Treat Rev. 2010 Nov;36 Suppl 3:S62-6. doi: 10.1016/S0305-7372(10)70022-0. Cancer Treat Rev. 2010. PMID: 21129613 Review.
-
[Her2 positive breast cancer: practices].Bull Cancer. 2011 Feb;98(2):154-63. Bull Cancer. 2011. PMID: 21591301 Review. French.
-
New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?Cancer Treat Rev. 2012 Aug;38(5):494-504. doi: 10.1016/j.ctrv.2012.01.001. Epub 2012 Feb 3. Cancer Treat Rev. 2012. PMID: 22305205 Review.
-
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. doi: 10.1038/ncponc1156. Epub 2008 Jul 1. Nat Clin Pract Oncol. 2008. PMID: 18594499 Review.
Cited by
-
Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients.Curr Med Res Opin. 2016 Jun;32(6):991-6. doi: 10.1185/03007995.2016.1149056. Epub 2016 Mar 2. Curr Med Res Opin. 2016. PMID: 26824145 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous